Search
Results: 9296
Interview with Anne Duncan
Anne Duncan
Jan 01, 0001
In her January 7, 2014 interview with Cody Willis, Anne Duncan reminisces of her time at Winthrop from 1974-1978 as a Physical Education major. This interview was conducted for inclusion into the Louise Pettus Archives and...
Published by: Winthrop University
Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.
ADAM 17 (TNF-α converting enzyme, TACE) is a potential target for cancer therapy, but the small molecule inhibitors reported to date are not specific to this ADAM family member. This membrane-bound metalloproteinase is...
Faculty Members' Documentary Details Spartanburg's Duncan Park Stadium
Winthrop University
Jan 01, 0001
"Duncan Park Stadium: 85 Years of Baseball Memories" will air Oct. 20 and Oct. 24 on ETV. Faculty members Mark Nortz and Albert Bolognese started working on the documentary in January 2010.
Published by: Winthrop University
Quantifying Drug-Induced Bone Marrow Toxicity Using a Novel Haematopoiesis Systems Pharmacology Model.
Chiara Fornari, Lenka Oplustil O'Connor, Carmen Pin, Aaron Smith, James WT Yates, SY Amy Cheung, Duncan I Jodrell, Jerome T Mettetal, Teresa A Collins
Feb 06, 2020
Haematological toxicity associated with cancer therapeutics is monitored by changes in blood cell count, and their primary effect is on proliferative progenitors in the bone marrow. Using observations in rat bone marrow and...
Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.
Siang-Boon Koh, Yann Wallez, Charles R Dunlop, Sandra Bernaldo de Quirós Fernández, Tashinga E Bapiro, Frances M Richards, Duncan I Jodrell
Jun 29, 2018
Combination of cytotoxic therapy with emerging DNA damage response inhibitors (DDRi) has been limited by tolerability issues. However, the goal of most combination trials has been to administer DDRi with standard-of-care doses...
Animals Antineoplastic Combined Chemotherapy Protocols Cell Cycle Proteins Cell Line Tumor Cell Proliferation Checkpoint Kinase 1 DNA Damage DNA Replication Deoxycytidine Drug Synergism Female Humans Mice Mice Inbred BALB C Mice Nude Nuclear Proteins Protein-Tyrosine Kinases Xenograft Model Antitumor Assays Gemcitabine
Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase
Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase
Claire M Connell, Rebecca Brais, Hayley Whitaker, Sara Upponi, Ian Beh, Jane Risdall, Pippa Corrie, Tobias Janowitz, Duncan I Jodrell
Feb 15, 2020
BACKGROUND:Pancreatic adenosquamous carcinoma has a poor prognosis, with limited prospective trial data to guide optimal treatment. The potential impact of drug metabolism on the treatment response of patients with pancreatic...
Published by: BMC cancer
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Aurélie Courtin, Frances M Richards, Tashinga E Bapiro, Jo L Bramhall, Albrecht Neesse, Natalie Cook, Ben-Fillippo Krippendorff, David A Tuveson, Duncan I Jodrell
Feb 12, 2020
Capecitabine (CAP) is a 5-FU pro-drug approved for the treatment of several cancers and it is used in combination with gemcitabine (GEM) in the treatment of patients with pancreatic adenocarcinoma (PDAC). However, limited...
Animals Antineoplastic Combined Chemotherapy Protocols Capecitabine Carcinoma Pancreatic Ductal Cell Line Tumor Cytidine Deaminase Deoxycytidine Disease Models Animal Drug Screening Assays Antitumor Fluorouracil Mice Mice Transgenic Neoplasm Transplantation Pancreatic Neoplasms prodrugs Tissue Distribution Gemcitabine
Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase
Claire M Connell, Rebecca Brais, Hayley Whitaker, Sara Upponi, Ian Beh, Jane Risdall, Pippa Corrie, Tobias Janowitz, Duncan I Jodrell
Jan 09, 2020
Cytidine Deaminase DRUG METABOLISM Gemcitabine Pancreatic Adenosquamous Carcinoma Antimetabolites Antineoplastic Carcinoma Adenosquamous Chemotherapy Adjuvant Cytidine Deaminase Deoxycytidine Female Gene Expression Humans Immunohistochemistry Magnetic Resonance Imaging Middle Aged Pancreatic Neoplasms Recurrence Retreatment Tomography X-Ray Computed Treatment Outcome Gemcitabine
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
Charles R. Dunlop, Yann Wallez, Timothy Isaac Johnson, Sandra Bernaldo de Quirós Fernández, Stephen T. Durant, Elaine B. Cadogan, Alan Lau, Frances M. Richards, Duncan I. Jodrell
Feb 09, 2021
Abstract: Background: Personalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR...
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
Charles R. Dunlop, Yann Wallez, Timothy Isaac Johnson, Sandra Bernaldo de Quirós Fernández, Stephen T. Durant, Elaine B. Cadogan, Alan Lau, Frances M. Richards, Duncan I. Jodrell
Aug 03, 2021
Abstract: Background: Personalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR...
The use of error-category mapping in pharmacokinetic model analysis of dynamic contrast-enhanced MRI data.
Andrew B Gill, Gayathri Anandappa, Andrew J Patterson, Andrew N Priest, Martin J Graves, Tobias Janowitz, Duncan I Jodrell, Tim Eisen, David J Lomas
Feb 10, 2015
DCE-MRI error analysis metastatic renal cell carcinoma pharamacokinetic modeling REPEATABILITY Algorithms Antibodies Monoclonal Humanized Area Under Curve Bevacizumab Carcinoma Renal Cell Contrast Media Humans Image Processing Computer-Assisted Kidney Neoplasms Magnetic Resonance Imaging Models Theoretical Neoplasm Metastasis Reproducibility of Results Software
Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach.
Timothy I Johnson, Christopher J Minteer, Daniel Kottmann, Charles R Dunlop, Sandra Bernaldo de Quirós Fernández, Larissa S Carnevalli, Yann Wallez, Alan Lau, Frances M Richards, Duncan I Jodrell
Jul 26, 2021
BACKGROUND: Chemotherapy and targeted agent anti-cancer efficacy is largely dependent on the proliferative state of tumours, as exemplified by agents that target DNA synthesis/replication or mitosis. As a result, cell cycle...
Cancer Cell Cycle Combination treatment high throughput screening synchronisation Cell Culture Techniques Cell Cycle Cell Line Tumor Cell Proliferation Cell Survival Deoxycytidine Drug Screening Assays Antitumor Drug Synergism HeLa Cells High-Throughput Screening Assays Humans MCF-7 Cells Neoplasms Nocodazole Piperazines Pyridines Small Molecule Libraries Time Factors Tubulin Modulators Gemcitabine
Model selection and sample size adaptation
RIGHTS : This article is licensed under the BioMed Central licence at http://www.biomedcentral.com/about/license which is similar to the 'Creative Commons Attribution Licence'. In brief you may : copy, distribute, and display...
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.
Natalie Cook, Kristopher K Frese, Tashinga E Bapiro, Michael A Jacobetz, Aarthi Gopinathan, Jodi L Miller, Sudhir S Rao, Tim Demuth, William J Howat, Duncan I Jodrell, David A Tuveson
Sep 03, 2020
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal disease that is refractory to medical intervention. Notch pathway antagonism has been shown to prevent pancreatic preneoplasia progression in mouse models, but potential...
Amyloid Precursor Protein Secretases Animals Carcinoma Pancreatic Ductal Cell Line Tumor Cell Proliferation Cyclic S-Oxides Deoxycytidine Drug Synergism Drug Therapy Combination Endothelial Cells Humans Hypoxia Mice Mice Mutant Strains Necrosis Pancreatic Neoplasms Protease Inhibitors Receptors Notch Signal Transduction Thiadiazoles Translational Research Biomedical Gemcitabine
Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach.
Timothy I Johnson, Christopher J Minteer, Daniel Kottmann, Charles R Dunlop, Sandra Bernaldo de Quirós Fernández, Larissa S Carnevalli, Yann Wallez, Alan Lau, Frances M Richards, Duncan I Jodrell
Jun 28, 2021
Background
Chemotherapy and targeted agent anti-cancer efficacy is largely dependent on the proliferative state of tumours, as exemplified by agents that target DNA synthesis/replication or mitosis. As a result, cell...
Published by: EBioMedicine
Depletion of Macrophages Improves Therapeutic Response to Gemcitabine in Murine Pancreas Cancer.
Soeren M Buchholz, Robert G Goetze, Shiv K Singh, Christoph Ammer-Herrmenau, Frances M Richards, Duncan I Jodrell, Malte Buchholz, Patrick Michl, Volker Ellenrieder, Elisabeth Hessmann, Albrecht Neesse
Sep 01, 2020
BACKGROUND: The tumor microenvironment (TME) is composed of fibro-inflammatory cells and extracellular matrix (ECM) components. However, the exact contribution of the various TME compartments towards therapeutic response is...
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
Charles R. Dunlop, Yann Wallez, Timothy Isaac Johnson, Sandra Bernaldo de Quirós Fernández, Stephen T. Durant, Elaine B. Cadogan, Alan Lau, Frances M. Richards, Duncan I. Jodrell
Oct 27, 2020
Abstract: Background: Personalised medicine strategies may improve outcomes in pancreatic ductal adenocarcinoma (PDAC), but validation of predictive biomarkers is required. Having developed a clinical trial to assess the ATR...
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
Charles R Dunlop, Yann Wallez, Timothy Isaac Johnson, Sandra Bernaldo de Quirós Fernández, Stephen T Durant, Elaine B Cadogan, Alan Lau, Frances M Richards, Duncan I Jodrell
Jul 01, 2020
Animals Antineoplastic Combined Chemotherapy Protocols Ataxia Telangiectasia Mutated Proteins Carcinoma Pancreatic Ductal Cell Line Tumor Cell Proliferation Deoxycytidine Drug Synergism Female Gene Knockout Techniques Humans Indoles Mice Mice 129 Strain Mice Inbred C57BL Morpholines Pancreatic Neoplasms Pyridines Pyrimidines Quinolines RNA Small Interfering Sulfonamides Sulfoxides Xenograft Model Antitumor Assays Gemcitabine
SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
Albrecht Neesse, Kristopher K Frese, Derek S Chan, Tashinga E Bapiro, William J Howat, Frances M Richards, Volker Ellenrieder, Duncan I Jodrell, David A Tuveson
Feb 12, 2020
DESIGN: Pharmacokinetic and pharmacodynamic parameters of cremophor-paclitaxel, nab-paclitaxel (human-albumin-bound paclitaxel, Abraxane) and a novel mouse-albumin-bound paclitaxel (m-nab-paclitaxel) were evaluated in...
pancreatic cancer Adenocarcinoma Albumin-Bound Paclitaxel Albumins Animals Animals Genetically Modified Antineoplastic Agents Phytogenic Collagen Dose-Response Relationship Drug Mice Osteonectin Paclitaxel Pancreatic Neoplasms Pharmaceutical Vehicles Polyethylene Glycols Xenograft Model Antitumor Assays
|
|< |
< |
1 |